You searched for: sham (Engelska - Kroatiska)

sham
placebo

sham n = 76
placebo postupak n = 76

7.3 (sham)
7,3 (placebo postupak)

sham- sham/sham+ discontinued
prekid liječenja

sham/ eylea 2mg (n = 31)
placebo postupak/ eylea 2mg (n = 31)

the first study compared lucentis with a sham injection.
prvo ispitivanje uspoređivalo je lucentis s injekcijom placeba.

patients in the sham group were eligible to receive eylea from week 24.
bolesnici u skupini s placebo postupkom bili su pogodni za primanje lijeka eylea od 24. tjedna.

a total of 77 patients were randomised to receive ozurdex and 76 to receive sham.
ukupno 77 bolesnika odabranih slučajnim odabirom primalo je ozurdex, a 76 primalo je placebo postupak.

a total of 229 patients were randomised to receive dexamethasone 350 µg or 700 µg implants or sham.
ukupno 229 bolesnika odabranih slučajnim odabirom primilo je implantate deksametazona od 350 µg ili 700 µg ili placebo postupak.

a total of 351 were randomised to ozurdex, 347 to dexamethasone 350 µg and 350 patients to sham.
ukupno ih je 351 randomizirano u skupinu koja je primila ozurdex, 347 deksametazon 350 µg i 350 placebo.

a proportion significantly higher with ozurdex compared to sham (p < 0.001)
a udio značajnije viši kod lijeka ozurdex u usporedbi s placebo postupkom (p < 0,001)

limited data from sham subjects who later received ranibizumab suggested that early initiation of treatment may be associated with better preservation of visual acuity.
ograničeni podaci dobiveni od ispitanika liječenih placebo postupkom koji su kasnije primili ranibizumab ukazuju da se rani početak liječenja može povezati s boljim očuvanjem vidne oštrine.

in myopic choroidal neovascularisation, eylea was investigated in a main study involving 122 patients, which compared eylea with a sham injection.
kod miopne koroidne neovaskularizacije, lijek eylea ispitivan je u glavnom ispitivanju koje je uključivalo 122 bolesnika, u kojem je lijek eylea uspoređen s fiktivnom injekcijom.

by day 180 the mean retinal thickness reduction (-119.3 microns) compared with sham was not significant.
na 180. dan prosječno smanjenje debljine mrežnice (-119,3 mikrona) u usporedbi s placebo postupkom nije bilo značajno.

a total of 36% of ozurdex treated patients discontinued study participation for any reason during the study compared with 57% of sham patients.
ukupno 36% bolesnika koji su primili ozurdex isključeno je iz ispitivanja zbog bilo kojeg razloga, u usporedbi s 57% bolesnika iz placebo skupine.

these proportions were maintained at week 100 with 76.8 % (n = 76) in the eylea group and 78% (n = 39) in the sham group.
ovi udjeli održani su do 100. tjedna, s 76,8% (n=76) u skupini s lijekom eylea i 78% (n=39) u skupini s placebo postupkom.